Phase 2b, randomized, double-blind, placebo-controlled study to evaluate the effects of EDP-938 in adult recipients of a hematopoietic cell transplant with acute upper respiratory tract infection due to respiratory syncymus virus.
COMMERCIAL CLINICAL TRIAL
Clinical trial information
- Promoter: ENANTA PHARMACEUTICALS, INC.
- Phase: II
- Execution start: 05/02/2021
- End of execution: 28/02/2023
- PI: PEDRO ANTONIO GONZALEZ SIERRA